Autopsy report · NCT00826930

Trans Sodium Crocetinate (TSC) Study of Intra-tumoral Oxygen Concentration, Safety, and Pharmacokinetics in Patients With High Grade Glioma

“Sponsor business decision, not based on safety or efficacy data.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months before it started.
• Ran for about 2 months before it stopped.
• 1 participant enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Diffusion Pharmaceuticals Inc

Sponsor type

Industry

Conditions

High Grade Glioma

Interventions

Trans Sodium Crocetinate (TSC)

Participants

1

Sites

1

Countries

United States

Trials that died the same way

• Study of RO7515629 in Participants With HLA-G Positive Solid Tumors
  “Sponsor decision (not related to safety, efficacy or quality).” (82% match in meaning)
• (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations
  “Sponsor decision, not related to safety concerns” (81% match in meaning)
• REGENETEN™ Bioinductive Implant System in Full-thickness Tears
  “Sponsor decision not related to safety.” (81% match in meaning)
• Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity
  “Company/sponsor business decision; not due to or related to any safety concerns” (80% match in meaning)
• A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer
  “This decision was conducted by the sponsor based on lack of efficacy and not driven by safety concerns.” (80% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.